70 Medical & Healthcare apps of Actelion Pharmaceuticals are listed with us |
Actelion PharmaceuticalsActelion was founded in December 1997 and has its headquarters in Allschwil near Basel (Switzerland). Its CEO and co-founder is cardiologist Jean-Paul Clozel.
Actelion scientists were among the first to work in the field of endothelian receptor antagonists. The company name might be a reminder for its first product, an endothelian receptor antagonist and the verb "action", "act upon". Actelion was initially financed with venture capital provided through a syndicate including Sofinnova and HealthCap.
Actelion specializes in orphan diseases. Often R&D investments in such diseases are low because companies see no ROI. Obviously, this is a serious problem for patients affected by a rare disease. Orphan diseases often affect very vulnerable patient groups such as children; Actelion keeps investing in such areas: |